文献速递湿疹皮炎与荨麻疹

口服JAK/SYK双抑制剂ASN002治疗中重度特应性皮炎的随机双盲安慰剂对照研究

The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study.
PubMed 文献 · Br J Dermatol · 2019-05-06

这项随机双盲安慰剂对照的1b期研究纳入36例中重度特应性皮炎患者,按3:1随机分配至ASN002或安慰剂组,评估20mg、40mg、80mg每日一次共28天的疗效与安全性。结果显示ASN002在EASI 50应答率和瘙痒改善方面优于安慰剂,且呈剂量依赖性降低Th1/Th2/Th17/Th22相关血清生物标志物,不良事件总体轻微。

要点

  • ASN002呈剂量依赖性血浆暴露,显著下调Th1/Th2/Th17/Th22相关血清生物标志物。

核心结论

  • 在中重度特应性皮炎患者中,ASN002显示出强效且起效快的疗效,并伴随系统性炎症的改善。

研究设计与样本

  • 随机双盲安慰剂对照1b期研究,共纳入36例中重度特应性皮炎患者,按3:1随机分配至ASN002或安慰剂组。
  • 研究设三个剂量队列(20mg、40mg、80mg每日一次),治疗周期为28天。

主要发现

  • 不良事件总体轻微且各组相似;ASN002呈剂量依赖性血浆暴露且个体间变异低。
  • ASN002显著下调多种参与Th1、Th2和Th17/Th22免疫的血清生物标志物,并降低动脉粥样硬化相关标志物E选择素/SELE。

临床怎么用

  • ASN002作为口服JAK/SYK双抑制剂,在中重度特应性皮炎中显示出快速起效的疗效信号,40mg和80mg剂量与安慰剂相比在EASI 50和瘙痒改善方面有统计学差异。
  • 治疗期间需关注不良事件,原文报告总体轻微且各组相似,但样本量小需谨慎解读。

局限性

  • 研究为1b期小样本(36例)短期(28天)研究,各剂量组样本量小,疗效和安全性需更大规模长期研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: ASN002 is an oral dual inhibitor of Janus kinase and spleen tyrosine kinase, which are involved in the pathogenesis of atopic dermatitis (AD) through their regulatory role on T helper (Th)1, Th2 and Th17/Th22 pathways. OBJECTIVES: The objectives of this study were to evaluate the efficacy, safety, pharmacokinetics and effects on systemic biomarkers of ASN002 in patients with moderate-to-severe AD. Methods A total of 36 patients with moderate-to-severe AD were randomized (3 : 1) to ASN002 or placebo in the phase Ib study. Three dosage cohorts were studied over a 28-day period (20 mg, 40 mg and 80 mg once daily). RESULTS: ASN002 was superior to placebo for the proportion of patients achieving Eczema Area and Severity Index (EASI) 50 (20 mg 20%, P = 0·93; 40 mg 100%, P = 0·003; 80 mg 83%, P = 0·03; placebo 22%), EASI 75 (20 mg 0%, P = 0·27; 40 mg 71%, P = 0·06; 80 mg 33%, P = 0·65; placebo 22%) and in change from baseline in pruritus (20 mg -1·3 ± 2·1, P = 0·81; 40 mg -3·1 ± 2·7, P = 0·27; 80 mg -4·7 ± 2·1, P = 0·01; placebo -1·6 ± 1·8). Adverse events were generally mild and similar across all groups. ASN002 showed dose-dependent plasma exposure with low interpatient variability, significantly downregulated several serum biomarkers involved in Th1, Th2 and Th17/Th22 immunity, and decreased the atherosclerosis-associated biomarker E selectin/SELE. CONCLUSIONS: In patients with moderate-to-severe AD, ASN002 showed strong efficacy with rapid onset of action and associated improvements in systemic inflammation.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Bissonnette R, Maari C, Forman S, et al. The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study. Br J Dermatol. 2019. PMID: 30919407. doi:10.1111/bjd.17932

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。